Conceivable Life Sciences Secures $18 Million for AI-Powered IVF Automation
Conceivable Life Sciences, a pioneering biotech firm dedicated to transforming fertility care, has successfully closed an $18 million Series A financing round. This significant funding was led by ARTIS Ventures, with additional investments from Atlantic Health Venture Studio, Muse Capital, and Scrub Capital. Existing investors such as ACME Capital, Black Opal Ventures, and Cadence Healthcare Ventures also contributed, bringing the company’s total funding to over $39 million.
Conceivable aims to utilize this capital to advance its AI-powered automated IVF lab, setting a new benchmark in fertility treatment. The company has developed technology that combines AI and robotics to automate more than 200 intricate steps required in IVF embryo creation. Notably, Conceivable achieved a significant milestone with the world’s first fully automated intracytoplasmic sperm injection (ICSI), performed both onsite and remotely across 3,000 miles between reproductive cells and the embryologist operator in New York.
This groundbreaking achievement was highlighted during a mainstage presentation at the 2024 European Society of Human Reproduction and Embryology (ESHRE). The company’s interdisciplinary team of experts in embryology, automation, AI, robotics, advanced optics, and machine vision is transforming the outdated model of IVF labs, which have remained largely manual and artisanal despite advancements in other medical fields.
The newly acquired funding will support a commercial pilot, including a 100-patient Institutional Review Board (IRB) study currently in progress. Preliminary results from a previous IRB study showed promising outcomes, with 22 pregnancies achieved after the first embryo transfer using Conceivable’s first-generation AI platform. The company is preparing for a U.S. launch targeted for early 2026.
The investment underscores the transformative potential of Conceivable’s technology, which aims to democratize IVF by reducing costs and increasing accessibility. The high costs of current IVF treatments mean that many individuals cannot access this life-changing therapy. Conceivable’s innovations promise to make starting a family a reality for many more individuals by providing a scalable solution that delivers equity in fertility care.
Conceivable’s approach to IVF, combining AI and cutting-edge robotics, will transform the field worldwide, catalyzing a new era of quality, scale, accessibility, and follow-on innovation. The company’s technology has the potential to address the significant unmet demand for IVF, particularly in regions where access to fertility care is limited due to high costs or proximity to care.
The funding will also support Conceivable’s ongoing commercial pilot program in Mexico City, further advancing the company’s mission to expand access to fertility care. With this significant investment, Conceivable is poised to revolutionize the future of fertility treatment, making IVF more accessible and affordable for individuals around the world. The company’s commitment to transforming the outdated model of IVF labs and delivering high-quality, scalable fertility care positions it as a leader in the field of reproductive medicine.
See more funded startups in USA.